The DIA EuroMeeting remained focused on new technologies regarding clinical trials. Biosimulation, comparability and the new EMEA rules on biosimilars attracted crowds today. European regulators are well on their way toward creating a new market niche in biosimilars. They're years ahead of the U.S. and likely to be very influential in determining how generic biotech products start reaching the market. Look for lots of resistance from the U.S. biotech industry, but some trends are irresistible. - John Carroll